Primary Objective:

• Response rate (by contrast CT scan)

Secondary Objectives:

• Progression-free survival (PFS)
• Overall survival (OS)

The duration of the study for each patient will include an up to 6-week screening phase, 12 weeks treatment phase (including a resting period of 2 weeks) followed by a long-term follow-up.

Inclusion criteria:

• Pathologically proven locally advanced, inoperable, confirmed by PET scan (thorax/ upper abdomen) to be International stage III (2009) NSCLC and without multifocal tumours in the lung
• Disease volume encompassible within a tolerable Planning Target Volume treated to 66 Gy
• FEV1 (Force Expiratory Volume in 1 Second) >1000 ml
• Hemoglobin ≥ 9.0 g/dl
• Absolute neutrophil count (ANC) ≥ 1,500/mm3
• Platelet count ≥ 100,000/mm3
• Total bilirubin ≥ 1.5 times the upper limit of normal
• ALT (Alanine Aminotransferase) and AST (Aspartate transaminase) ≤ 2.5 x upper limit of normal (≤ 5 x upper limit of normal for patients with liver derangement)
• ECOG (Eastern Cooperative Oncology Group) PS 0-1

Exclusion criteria:

• Previous treatment with chest radiotherapy, chemotherapy or molecularly targeted agents
• Inadequate lung function (Exercise tolerance less than 1 FOS/Fight of stairs, FEV1 < 1 L/sec, or raised pCO2)
• History of hypersensitivity or contraindication to the study drugs or pre-medications or products formulated in polysorbate 80
• Pregnant or breast-feeding women, or women with child-bearing potential who are not following an effective method of contraception and/or who are unwilling or unable to be tested for pregnancy (either by serum or urine pregnancy test before study entry
• Participation in a clinical trial with any investigational drug used and within 30 days prior to study entry

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.